ERAS · Erasca, Inc. · Stock research

Current Thesis

• Pan-RAS developer whose defining binary already detonated. ERAS-0015 dose-escalation data (2026-04-27) read best-in-class 62% ORR in 2L+ KRAS G12X NSCLC, 75% in post-ICI/platinum patients, 64% at the 24–32 mg expansion dose, 40–50% in 2L pancreatic, no DLTs through 40 mg yet shares fell ~48% the next session on overhangs that printed alongside the efficacy rather than on the numbers themselves.
• The recovery leg is largely spent. From the 2026-05-07 low near $10.16 the stock round-tripped to a $16.01 close (2026-06-26, +7.1% on the day even as class-action headlines hit), back above BofA's $16 target and into the lower half of the unfilled April gap. A fresh long here pays up for a recovered legal binary grinding into overhead supply while the dominant re-rating catalyst sits in an undated H2-2026 window.
• Three overhangs remain live: the 2026-04-24 Revolution Medicines letter alleging ERAS-0015 infringes US Patent 12,409,225; a treatment-related Grade-5 pneumonitis death disclosed only on the after-hours call; and a securities class-action filed 2026-06-24 to 2026-06-26 (S.D. Cal., class period 2025-01-14 to 2026-04-26, lead-plaintiff deadline 2026-08-10). This reads as a special situation, not an accelerating narrative.

Bullish and bearish views on Erasca, Inc.

The model's bull view on Erasca, Inc. (ERAS), in brief: (data) ERAS-0015 efficacy is genuinely best-in-class for the pan-RAS pathway: 62–75% unconfirmed NSCLC ORR and 40–50% pancreatic ORR (2026-04-27) at doses with no DLTs through 40 mg and no treatment-attributed discontinuations. The bear view: (legal) The RevMed letter (2026-04-24) is unresolved and demands Erasca cease all US making, using, and selling of ERAS-0015 outside the Hatch-Waxman safe harbor. Both cases follow in full.

Bull Case

• (data) ERAS-0015 efficacy is genuinely best-in-class for the pan-RAS pathway: 62–75% unconfirmed NSCLC ORR and 40–50% pancreatic ORR (2026-04-27) at doses with no DLTs through 40 mg and no treatment-attributed discontinuations. Revolution Medicines' RMC-6236 set the comparison bar; the trade press called the numbers a "home run."
• (analyst) Sell-side capitulation reversed on 2026-06-04: BofA moved Underperform→Neutral, PT $9→$16, citing pan-RAS activity that "appears real"; KeyBanc turned constructive the same day. Consensus 12-month PT sits ~$15.6 with a high near $18.75, so the current tape has already met the average target.
• a clean readout there re-rates the platform without the '225 cloud that hangs over ERAS-0015.
• (balance sheet) Cash runway guided into H2 2028 (reaffirmed in the 2026-01-12 milestones release), pushing terminal dilution risk past the next two data cycles and giving the litigation binaries time to play out without a forced raise.
• (structure) 310.98M shares, ~$4.98B market cap, 52-week range $1.21–$24.28: a small-cap with violent two-way gamma. A ~60% bounce off the May low that absorbed the class-action filings shows recovery momentum capable of pressing toward the $19 pre-crash shelf if a catalyst re-engages buyers.

Bear Case

• (legal) The RevMed letter (2026-04-24) is unresolved and demands Erasca cease all US making, using, and selling of ERAS-0015 outside the Hatch-Waxman safe harbor. RevMed is far better capitalized; escalation to a filed suit or any injunctive relief on the lead asset is a −30%-plus event with no resolution date attached.
• (legal) The securities-fraud wave (filed 2026-06-24 to 2026-06-26, S.D. Cal.) alleges the "best-in-class" comparisons rested on cross-study analyses rather than head-to-head trials and that safety and IP risks were concealed. Backward-looking, but it caps multiple expansion and feeds discovery on the exact data set RevMed is attacking. Lead-plaintiff deadline 2026-08-10.
• (safety) The Grade-5 pneumonitis death (66-year-old, pancreatic, 24 mg) was disclosed only on the 2026-04-27 call, not in the press release an information-asymmetry problem as much as a tolerability one. Expansion-cohort safety is the gating datapoint before any dose-registration path is credible.
• (technical) Price has recovered into overhead supply: the April gap-down (~$19→~$10) is still unfilled, the $19 pre-crash shelf is stacked with trapped longs, and at ~$16 the stock trades at consensus PT with the average analyst already neutral. Reward-to-risk on a fresh entry compresses as the gap fills.
• (catalyst gap) The one event that could justify chasing ERAS-4001 Phase 1 data is undated inside H2 2026, so a position taken now carries weeks of theta and legal-headline risk with no scheduled payoff.

Setup & Price Structure

• Reference tape: $16.01 close (2026-06-26), ~65% off the pre-crash $19 shelf lows and back above the $16 round number that doubles as BofA's target.
• Base to defend: the 2026-05-07 low near $10.16. A hold above ~$10 keeps the recovery structure intact; that zone is where the post-print sellers exhausted.
• Overhead supply: the unfilled April gap runs ~$10 to ~$19; the stock is now mid-gap. The $19 pre-crash shelf and the January highs are the trapped-buyer wall. 52-week range $1.21–$24.28 shows how thin and reflexive the float trades.
• Read: strength here is mean-reversion into resistance, not an accelerating breakout. Absent a fresh catalyst, the higher-probability path is chop between the ~$10 base and the ~$19 supply band, with legal headlines the dominant swing factor. Stand aside on fresh entries until either the gap fills and holds on volume or a dated ERAS-4001 catalyst appears.

Catalyst Calendar (next 30 days)

• Q2 2026 earnings call est. ~2026-08-07 (early-to-mid August); expected to carry a cash-runway and potential ATM update. Just outside 30 days but the next scheduled corporate event.
• Securities class-action lead-plaintiff deadline 2026-08-10. A legal milestone, not a price catalyst, but a marker for continued discovery risk.
• No confirmed binary readout falls inside the next 30 days; the near-term tape is driven by legal-headline flow and XBI beta, not a dated event.

Elapsed catalysts

• ERAS-4001 (BOREALIS-1) initial Phase 1 monotherapy data guided H2 2026, still undated as of 2026-07-12. The cleanest IP-independent re-rate; unlikely to print inside this 30-day window. _(passed 7d ago)_

What Would Change Our Mind

• Bearish break: a weekly close below $10 loses the post-crash recovery base and reopens the sub-$10 April lows; a filed RevMed suit or any injunction motion on ERAS-0015 is the fundamental version of the same break and would force a re-rate lower regardless of the tape.
• Bullish re-engagement: a dated ERAS-4001 Phase 1 readout, a RevMed settlement or dismissal removing the '225 cloud, or a clean gap-fill through ~$19 on expanding volume would convert this from a recovered legal binary into an initiable momentum setup. Until one of those lands, the setup stays a low-conviction watch.

Correlation Notes

• Inverse legal tether to Revolution Medicines (RMVL/RMC): headlines on the '225 patent move the two names in opposite directions a RevMed litigation win is an Erasca drawdown and vice versa. The pan-RAS/pan-KRAS efficacy comparison also links their clinical read-throughs.
• High XBI beta: as a sub-$5B clinical-stage name with a wide 52-week range, ERAS amplifies small-cap biotech risk sentiment and rate-driven XBI swings; a risk-off leg in the group would hit it harder than the index.
• Read-through to KRAS/RAS peers (RMC, BridgeBio-adjacent RAS programs, other pan-RAS entrants): sector safety signals particularly pneumonitis or DLT reports can re-price ERAS-0015 tolerability assumptions independent of Erasca's own disclosures.